From the publishers of JADPRO

Chronic Lymphocytic Leukemia Resource Center

Advertisement

ASCO Annual Meeting Abstracts

Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study

British Journal of Haematology

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients

Blood

Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up

Journal of Clinical Oncology

Coverage and cost-of-care links: Addressing financial toxicity among patients with hematologic cancer and their caregivers

British Journal of Haematology

FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?

Clinical Lymphoma, Myeloma, & Leukemia

SOHO state of the art updates and next questions--New targetable pathways in chronic lymphocytic leukemia

Cancers (Basel)

The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: Future perspectives

New England Journal of Medicine

Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia

Lancet

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label single-arm, phase 1-2 study

ASCO 2023 Abstracts

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (ALLIANCE)

New England Journal of Medicine

First-line venetoclax combinations in chronic lymphocytic leukemia

British Journal of Haematology

Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia

British Journal of Haematology

From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics

Clinical Lymphoma, Myeloma, & Leukemia

Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: results from a multi-center international study.

Leukemia and Lymphoma

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study

Blood

Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: Updated interim analysis of FLAIR study

American Journal of Hematology

DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study

JAMA

Diagnosis and treatment of chronic lymphocytic leukemia: A review

British Journal of Haematology

Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge

Blood

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

British Journal of Haematology

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

Blood

Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): The Glow Study

Blood

High cell death rates at start of ibrutinib therapy predict for deeper remissions in patients with chronic lymphocytic leukemia (CLL)

JAMA

Diagnosis and treatment of chronic lymphocytic leukemia: A review

American Journal of Hematology

BTKi bonanza in CLL/SLL: Sorting out the differences

New England Journal of Medicine

Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia

Clinical Lymphoma Myeloma and Leukemia

SOHO state of the art updates and next questions - Infections in chronic lymphocytic leukemia patients: Risks and management

Blood

Final analysis of the prospective multicenter CLL2-GIVe trial of obinutuzumab (GA101, G), ibrutinib (I), and venetoclax (Ve) in untreated patients with CLL with 17p deletion/TP53 mutation

Blood

Genetic markers and front line FCR/BR vs. RVe, GVe and GIVe treatment: Outcome results from the CLL13/GAIA trial

American Journal of Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center single-arm, open-label, phase 2 study

Blood

Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

FDA.gov

FDA approves zanubrutinib for CLL or SLL

Blood

Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study

European Hematology Association 2022 Congress Abstract

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

Management of Atrial Fibrillation in Patients With CLL on BTK Inhibitors

The Importance of Shared Decision-Making in the Frontline Setting

Venetoclax Alone and In Combination: Overcoming Ibrutinib Resistance 